Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2025 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference

BASKING RIDGE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
January 23, 2025 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

Data corroborate previously reported preclinical data demonstrating certepetide’s ability to enhance the effectiveness of immunotherapy Preliminary results to be presented at the 2025 ASCO...
January 22, 2025 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Data reported positive trend in overall survival, including 4...
January 15, 2025 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

BASKING RIDGE, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment...
December 10, 2024 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

BASKING RIDGE, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment...
December 03, 2024 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging

BASKING RIDGE, N.J. and HOUSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for...
November 19, 2024 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’

Award recognizes Lisata’s data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors Annual BioTech Breakthrough Award is devoted...
November 12, 2024 16:05 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. ...
November 06, 2024 09:23 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

BASKING RIDGE, N.J. and HELSINKI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the...
November 06, 2024 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced...